Bortezomib (B) — Competitive Intelligence Brief

Bortezomib (B) (Bortezomib (B)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

marketed Proteasome inhibitor 26S proteasome Oncology Small molecule

Target snapshot

Bortezomib (B) (Bortezomib (B)) — National Cancer Institute (NCI). Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bortezomib (B) TARGET	Bortezomib (B)	National Cancer Institute (NCI)	marketed	Proteasome inhibitor	26S proteasome
Velcade	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Velcade	Velcade	University of Arkansas	marketed		26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
Bortezomib +Dexamethasone regimen	Bortezomib +Dexamethasone regimen	Assistance Publique - Hôpitaux de Paris	phase 3	Proteasome inhibitor + corticosteroid combination	26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone)
Cyclophosphamide + Bortezomib + Dexamethasone regimen	Cyclophosphamide + Bortezomib + Dexamethasone regimen	Assistance Publique - Hôpitaux de Paris	phase 3	Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid)	DNA (cyclophosphamide); 26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-11-03 — Velcade · 8962572 · Formulation · US
• 2042-09-23 — Velcade · 11752164 · Method of Use · US
• 2042-09-23 — Velcade · 11679119 · Method of Use · US
• 2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class